Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Monoclonal Antibodies
Phase II study shows combination improves survival of metastatic melanoma patients
June 18th, 2007
Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology Annual Meeting. In this phase II clinical trial of 53 patients, tumor growth was delayed by almost six months, whereas, typically, these cancers begin spreading again eight weeks after chemotherapy treatment, researchers say. The researchers from Mayo Clinic and the North Central Cancer Treatment Group (http://ncctg.mayo.edu/) (NCCTG), caution that while the findings are...
Source: Health & Medicine Week (2007-06-18)
|
